/

ENSC

Ensysce Biosciences, Inc.Closed

0.5725+0.02 +2.99%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 0.5625 −1.75%

Open

0.5358

Prev close

0.5559

Day range

0.53180.6200

52-week range

0.23002.75

Volume

1.20M0.08×

Mkt cap

11.14M

P/E ttm

—

Fwd P/E

-11.45

EPS ttm

-2.47

Div yield

0.00%

Earnings

—

From 52w high

−79.18%

Price Chart

Yahoo Finance · delayed

ENSCOct 13, 2026O 0.5360H 0.6200L 0.5320C 0.5730+0.0170 (+3.06%)Vol 1.21M

SMA 500.4305
SMA 2000.4644

1Y change −74.53% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ENSC Ensysce Biosciences, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +33.26%
1 month: +17.66%
3 months: +95.56%
6 months: +10.19%
Year to date: −37.72%
1 year: −75.30%

Valuation & ownership

Market cap: 11.14M
Enterprise value: 10.33M
P/E (ttm): —
Forward P/E: -11.45
PEG ratio: —
Price / book: —
Price / sales (ttm): 2.47
EV / EBITDA: —
EPS (ttm): -2.47
EPS (forward): -0.0500
Beta (5y monthly): 1.02
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 19.46M
Float: 18.54M
Short % of float: 5.56%
Short ratio (days): 2.14
Held by insiders: 4.72%
Held by institutions: 4.65%
Avg volume (3m): 14.17M
50-day average: 0.4247
200-day average: 0.4671
52-week change: −75.30%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): overbought 74.6
vs 50-day SMA: +33.09%
vs 200-day SMA: +23.38%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 8.34%
Realised vol (20d, ann.): 76.5%
From 52-week high: −79.16%
From 52-week low: +149.13%

ANR

Analyst Consensus

1 analysts

Consensus

—

Mean target

8.25

+1,341.05% implied

Low 8.25Median 8.25High 8.25

Recommendation trend

Now0 / 0 / 0
1m ago0 / 0 / 0

Buy / hold / sell counts

DES

About Ensysce Biosciences, Inc.

Yahoo Finance profile

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder. Further, It develops neuroplastogenic therapies and psychedelic-derived molecules for severe chronic pain, particularly complex regional pain syndrome (CRPS). Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 8
Headquarters: La Jolla, CA, United States
Website: ensysce.com
Officers: Dr. D. Lynn Kirkpatrick Ph.D. CEO & Director
Mr. David C. Humphrey CPA CFO, Secretary & Treasurer
Mr. Geoffrey Birkett

SEAS

Seasonality · ENSC

2018–2026 · monthly returns

Strongest month Dec +11.37%Weakest month Feb −16.67%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-21.1	-14.2	-13.5	-31.0	-24.5	3.2	-12.8	55.3	5.9	37.6			−37.8%
2025	-15.6	-21.6	-52.5	18.0	-26.5	0.5	-6.3	0.0	13.4	-8.0	-18.8	-48.0	−88.7%
2024	52.8	-42.5	-15.2	-25.1	-2.9	-12.0	-11.1	-12.2	-39.2	140.0	-14.2	9.9	−48.8%
2023	-6.7	-30.1	-17.2	-22.8	-36.8	-24.1	12.5	-8.6	-25.4	-33.3	23.8	-7.0	−88.2%
2022	-63.0	-35.6	1.8	-3.5	-49.0	54.7	-40.7	-18.1	-49.1	-24.9	-10.2	-74.1	−99.2%
2021	0.0	13.3	-7.2	-2.7	8.8	4.6	-61.0	-44.1	-4.1	-27.4	-28.2	197.5	−62.2%
2020	-0.1	-0.1	5.0	-4.7	4.8	7.4	-10.9	0.3	2.3	1.2	3.3	11.2	+19.3%
2019	1.2	0.0	1.0	0.3	0.6	0.5	0.3	0.2	0.2	0.5	0.3	1.0	+6.1%
2018				-0.5	0.7	0.4	0.4	-0.1	0.6	-0.2	0.3	0.6	+2.3%

INSD

Insider Activity · ENSC

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Aug 6, 2026	Gower Robert GDirector	Purchase at price 0.48 - 0.50 per share.	908.6K	$444.17K
Apr 22, 2026	Gower Robert GDirector	Conversion of Exercise of derivative security at price 0.42 per share.	254.3K	$107.83K

ENSC

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ENSC

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Ensysce Biosciences, Inc.

Seasonality · ENSC

Insider Activity · ENSC

Congress Trades · ENSC

Investors Holding ENSC

Investors Holding ENSC

Congress Trades · ENSC

Insider Activity · ENSC

Seasonality · ENSC

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Ensysce Biosciences, Inc.

Financial Snapshot

Earnings & Dividends

News